Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker

BackgroundImproved insight into the molecular characteristics of the different ovarian cancer subgroups is needed for developing a more individualized and optimized treatment regimen. The aim of this study was to a) identify differentially expressed miRNAs in high-grade serous ovarian carcinoma (HGSC), clear cell ovarian carcinoma (CCC) and ovarian surface epithelium (OSE), b) evaluate selected miRNAs for association with clinical parameters including survival and c) map miRNA-mRNA interactions.MethodsDifferences in miRNA expression between HGSC, CCC and OSE were analyzed by global miRNA expression profiling (Affymetrix GeneChip miRNA 2.0 Arrays, n = 12, 9 and 9, respectively), validated by RT-qPCR (n = 35, 19 and 9, respectively), and evaluated for associations with clinical parameters. For HGSC, differentially expressed miRNAs were linked to differentially expressed mRNAs identified previously.ResultsDifferentially expressed miRNAs (n = 78) between HGSC, CCC and OSE were identified (FDR < 0.01%), of which 18 were validated (p < 0.01) using RT-qPCR in an extended cohort. Compared with OSE, miR-205-5p was the most overexpressed miRNA in HGSC. miR-200 family members and miR-182-5p were the most overexpressed in HGSC and CCC compared with OSE, whereas miR-383 was the most underexpressed. miR-205-5p and miR-200 members target epithelial-mesenchymal transition (EMT) regulators, apparently being important in tumor progression. miR-509-3-5p, miR-509-5p, miR-509-3p and miR-510 were among the strongest differentiators between HGSC and CCC, all being significantly overexpressed in CCC compared with HGSC. High miR-200c-3p expression was associated with poor progression-free (p = 0.031) and overall (p = 0.026) survival in HGSC patients. Interacting miRNA and mRNA targets, including those of a TP53-related pathway presented previously, were identified in HGSC.ConclusionsSeveral miRNAs differentially expressed between HGSC, CCC and OSE have been identified, suggesting a carcinogenetic role for these miRNAs. miR-200 family members, targeting EMT drivers, were mostly overexpressed in both subgroups, among which miR-200c-3p was associated with survival in HGSC patients. A set of miRNAs differentiates CCC from HGSC, of which miR-509-3-5p and miR-509-5p are the strongest classifiers. Several interactions between miRNAs and mRNAs in HGSC were mapped.

[1]  B. Davidson,et al.  miRNA profiling along tumour progression in ovarian carcinoma , 2011, Journal of cellular and molecular medicine.

[2]  A. Jazaeri,et al.  Choice of normal ovarian control influences determination of differentially expressed genes in ovarian cancer expression profiling studies. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  H. Dressman,et al.  MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. , 2009, Gynecologic oncology.

[4]  P. Wimberger,et al.  microRNA and the pathogenesis of ovarian cancer – a new horizon for molecular diagnostics and treatment? , 2012, Clinical chemistry and laboratory medicine.

[5]  Zhiwei Wang,et al.  Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. , 2009, Cancer research.

[6]  S. Rosenwald,et al.  Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients. , 2009, Gynecologic oncology.

[7]  Marek Svoboda,et al.  MicroRNAs in colorectal cancer: translation of molecular biology into clinical application , 2009, Molecular Cancer.

[8]  Tian-Li Wang,et al.  MicroRNA Expression and Identification of Putative miRNA Targets in Ovarian Cancer , 2008, PloS one.

[9]  E. Izaurralde,et al.  Gene silencing by microRNAs: contributions of translational repression and mRNA decay , 2011, Nature Reviews Genetics.

[10]  Joel Greshock,et al.  MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. , 2008, Cancer research.

[11]  I. Shih,et al.  Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. , 2004, The American journal of pathology.

[12]  K. Gautvik,et al.  POLD2 and KSP37 (FGFBP2) Correlate Strongly with Histology, Stage and Outcome in Ovarian Carcinomas , 2010, PloS one.

[13]  Alex E. Lash,et al.  Gene Expression Omnibus: NCBI gene expression and hybridization array data repository , 2002, Nucleic Acids Res..

[14]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[15]  H. Horvitz,et al.  MicroRNA expression profiles classify human cancers , 2005, Nature.

[16]  Christopher P Crum,et al.  The Tubal Fimbria Is a Preferred Site for Early Adenocarcinoma in Women With Familial Ovarian Cancer Syndrome , 2006, The American journal of surgical pathology.

[17]  G. Goodall,et al.  The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1 , 2008, Nature Cell Biology.

[18]  C. Croce,et al.  Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA , 2012, Proceedings of the National Academy of Sciences.

[19]  F. Slack,et al.  MicroRNAs: tools for cancer diagnostics , 2009, Gut.

[20]  N. Auersperg.  The Origin of Ovarian Carcinomas: A Unifying Hypothesis , 2011, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[21]  A. Langerød,et al.  AZGP1 and SPDEF mRNA expression differentiates breast carcinoma from ovarian serous carcinoma , 2013, Virchows Archiv.

[22]  R. Maciejewski,et al.  MicroRNAs and their role in gynecological tumors , 2011, Medicinal research reviews.

[23]  O. Kent,et al.  A resource for analysis of microRNA expression and function in pancreatic ductal adenocarcinoma cells , 2009, Cancer biology & therapy.

[24]  L. Qin,et al.  A microRNA survival signature (MiSS) for advanced ovarian cancer. , 2011, Gynecologic oncology.

[25]  H. Mackay,et al.  Clear cell carcinoma of the ovary: a report from the first Ovarian Clear Cell Symposium, June 24th, 2010. , 2011, Gynecologic oncology.

[26]  G. Hurteau,et al.  Stable expression of miR-200c alone is sufficient to regulate TCF8 (ZEB1) and restore E-cadherin expression , 2009, Cell cycle.

[27]  P. V. van Diest,et al.  Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer , 2001, The Journal of pathology.

[28]  Shelley Tworoger,et al.  A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. , 2008, Gynecologic oncology.

[29]  Shuang-Di Li,et al.  The role of microRNAs in ovarian cancer initiation and progression , 2010, Journal of cellular and molecular medicine.

[30]  Huan Yang,et al.  MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. , 2008, Cancer research.

[31]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[32]  J. Prat.  Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features , 2012, Virchows Archiv.

[33]  Ben Davidson,et al.  Epithelial–Mesenchymal Transition in Ovarian Carcinoma , 2012, Front. Oncol..

[34]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[35]  Muneesh Tewari,et al.  MiR‐221 and MiR‐222 alterations in sporadic ovarian carcinoma: Relationship to CDKN1B, CDKNIC and overall survival , 2010, Genes, chromosomes & cancer.

[36]  P. Morin,et al.  MicroRNAs in ovarian carcinomas. , 2010, Endocrine-related cancer.

[37]  I. Shih,et al.  Ovarian Low-grade and High-grade Serous Carcinoma: Pathogenesis, Clinicopathologic and Molecular Biologic Features, and Diagnostic Problems , 2009, Advances in anatomic pathology.

[38]  B. Møller,et al.  Cancer incidence, mortality, survival and prevalence in Norway , 2011 .

[39]  C. Croce,et al.  MicroRNA signatures in human ovarian cancer. , 2007, Cancer research.

[40]  J. Garber,et al.  A candidate precursor to serous carcinoma that originates in the distal fallopian tube (J Pathol 2007; 211: 26–35) , 2007, The Journal of pathology.

[41]  P. Leung,et al.  Ovarian surface epithelium: biology, endocrinology, and pathology. , 2001, Endocrine reviews.

[42]  R. Drapkin,et al.  Serous Carcinogenesis in the Fallopian Tube: A Descriptive Classification , 2008, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[43]  M. Gratacós,et al.  Allele variants in functional MicroRNA target sites of the neurotrophin‐3 receptor gene (NTRK3) as susceptibility factors for anxiety disorders , 2009, Human mutation.

[44]  S. Vasudevan.  Posttranscriptional Upregulation by MicroRNAs , 2012, Wiley interdisciplinary reviews. RNA.

[45]  B. Martínez-Delgado,et al.  The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients. , 2010, Endocrine-related cancer.

[46]  Zhihui Feng,et al.  A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer. , 2009, Gynecologic oncology.

[47]  Anne Cathrine Staff,et al.  ZNF385B and VEGFA Are Strongly Differentially Expressed in Serous Ovarian Carcinomas and Correlate with Survival , 2012, PloS one.

[48]  R. Berkowitz,et al.  Intraepithelial Carcinoma of the Fimbria and Pelvic Serous Carcinoma: Evidence for a Causal Relationship , 2007, The American journal of surgical pathology.

[49]  J. Zavadil,et al.  Efficient in vivo microRNA targeting of liver metastasis , 2011, Oncogene.

[50]  D. Marsh,et al.  Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer , 2012, BMC Cancer.

[51]  David P Turner,et al.  MicroRNA-mediated inhibition of prostate-derived Ets factor messenger RNA translation affects prostate-derived Ets factor regulatory networks in human breast cancer. , 2008, Cancer research.

[52]  Enrica Calura,et al.  Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections. , 2011, The Lancet. Oncology.

[53]  Artemis G. Hatzigeorgiou,et al.  Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer , 2008, Proceedings of the National Academy of Sciences.

[54]  C. Marshall,et al.  MicroRNA-200 Family Members Differentially Regulate Morphological Plasticity and Mode of Melanoma Cell Invasion , 2010, PloS one.

[55]  Jae Hoon Kim,et al.  MicroRNA Expression Profiles in Serous Ovarian Carcinoma , 2008, Clinical Cancer Research.

[56]  Ragnhild Sørum,et al.  Recommended reference: Cancer Registry of Norway. Cancer in Norway 2007 - Cancer incidence, mortality, survival and prevalence in Norway, Oslo: Cancer Registry of Norway, 2008. , 2007 .

[57]  J. Steitz,et al.  Switching from Repression to Activation: MicroRNAs Can Up-Regulate Translation , 2007, Science.

[58]  Yasutoshi Yamada,et al.  Tumor suppressive microRNA-1285 regulates novel molecular targets: Aberrant expression and functional significance in renal cell carcinoma , 2012, Oncotarget.

[59]  H. An,et al.  Deregulation of miR‐519a, 153, and 485‐5p and its clinicopathological relevance in ovarian epithelial tumours , 2010, Histopathology.

[60]  Thomas D. Schmittgen,et al.  Analyzing real-time PCR data by the comparative CT method , 2008, Nature Protocols.

[61]  Leila Mohammadi,et al.  BMC Cancer , 2001 .

[62]  C. Croce,et al.  A microRNA expression signature of human solid tumors defines cancer gene targets , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[63]  J. Steitz,et al.  Posttranscriptional activation of gene expression in Xenopus laevis oocytes by microRNA–protein complexes (microRNPs) , 2011, Proceedings of the National Academy of Sciences.